A Multicenter, Open-Label, Randomized Controlled Trial study of Secukinumab in the treatment of recurrent MOG Antibody-Associated Optic Neuritis (ChiCTR) - Oct 16, 2026 - P=N/A | N=128 | Not yet recruiting | Sponsor: Chinese People's Liberation Army General Hospital; Senior Department of Ophthalmology, Chinese People's Liberation Army General Hospital
New trial • Ocular Inflammation • Ophthalmology • Optic Neuritis
|